Brains Bioceutical Corp. has announced plans to list on Nasdaq, in what would be the first US public-market debut for a UK-based cannabinoid pharma manufacturer since GW Pharmaceuticals was acquired by Jazz in 2021.
The company, headquartered in Vancouver, British Columbia, operates one of the largest cannabinoid active pharmaceutical ingredient (API) manufacturing facilities in the world through its wholly owned subsidiary BSPG Laboratories in Kent.
A new deal, announced on November 05, 2026, and signed on October 31, 2026, will see SPAC Armada Acquisition Corp. III acquire the company at an implied pre-money equity value of approximately US$750m.
The combined company will operate as Brains Therapeutics Corp. and trade on NASDAQ under the ticker BAPI. Existing Brains shareholders are expected to roll 100% of their equity into the newly combined entity, meaning no cash-out for the current shareholder base. Both companies’ boards have unanimously approved the deal, and Armada III’s sponsor and certain Brains shareholders have now entered support and lock-up agreements.
Once shareholder approvals and NASDAQ regulatory clearances are completed, closing is expected in the second quarter of 2027.
The SPAC route has been a common mechanism for cannabis and cannabis-adjacent companies to offer their stocks on major exchanges. A wave of combinations in late 2020 and 2021 took several US consumer-facing cannabis names public on NASDAQ, including Weedmaps parent WM Technology (June 2021, ticker MAPS), Colombian cultivator and UK distributor Clever Leaves (December 2020, CLVR) and cannabis media company Leafly (February 2022, LFLY).
Brains’ facility in Kent produces pharmaceutical-grade cannabinoid APIs including CBD, delta-9 THC, delta-8 THC, CBN and CBG, along with drug intermediates and finished medical products.
It boasts regulatory experience across the United States, the UK, the EU, the UAE, Japan, Australia and Brazil, backed by Drug Master Files and Active Substance Master Files and controlled-substance licensing in each jurisdiction, and cites ‘one of South America’s largest pharmaceutical companies’ and ‘one of the world’s largest generic pharmaceutical companies’ among existing API customers.
The listing bid is framed around a growing proprietary and partnered drug pipeline that goes well beyond raw-material supply. Brains holds global commercial rights to an extended-release methazolamide formulation for glaucoma that has cleared a pivotal bioequivalence study under an FDA Special Protocol Assessment.
It also supplies clinical trial material to an NIH-funded Phase 3 study of a cannabinoid-based treatment for opioid use disorder, which has received US$18m in NIH funding and is enrolling approximately 450 subjects across seven sites. Brains holds an exclusive option to negotiate a licence to the programme.
Its pipeline also includes a proprietary oral capsule for epilepsy and an in-house sleep-disorders programme.
“We have spent years developing the manufacturing, regulatory and scientific foundation required to participate in the pharmaceutical market at scale,” said Rick Brar, Chief Executive Officer and Chairman of Brains Bioceutical.
“Today, Brains is not simply developing promising compounds. We have an established pharmaceutical-grade manufacturing platform, commercial customer relationships, extensive regulatory experience and a growing pipeline of proprietary and partnered drug programmes.”
Stephen Herbert, Chairman and Chief Executive Officer of Armada III, said the SPAC was ‘formed to identify a business with differentiated technology, a substantial addressable market and a management team capable of building significant long-term value’, adding that he believes ‘Brains meets those criteria’.
